Publications - Complications/ Morbidity

View All Publications
Title Credits Expiration Date
Case Studies in Pain Management Vol. 2, No. 2 Nociceptive and Neuropathic Pain Management 1 Sep 29, 2009
Case Studies in Breast Cancer Vol. 6, No. 5 HER2+ Breast Cancer Progressing After Adjuvant Therapy 1 Sep 29, 2009
Oncology Consultations Vol. 5, No. 1 Therapeutic Options for ER+/HER2- Breast Cancer 1 Jun 6, 2009
Case Studies in Ovarian Cancer Vol. 3, No. 1 Clinical Management of a Patient With Platinum-Resistant Ovarian Cancer 1 Jun 6, 2009
From Genome to Clinic: Translating Discoveries Into Practice

Targeting Growth Factor Receptors: Current Impact and Future Potential


Therapeutic Applications of Angiogenesis-Based Therapies

 		1 Jun 4, 2009
Rapid Reviews in Oncology: Update in Hematologic Malignancies Frontline Therapies for Multiple Myeloma: A New Landscape

Evolving Strategies in the Management of Patients With Chronic Lymphocytic Leukemia

Clinical Advances for Patients With Myelodysplastic Syndromes

 		1 Jun 3, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 3 Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma 1.5 May 28, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 2 Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma 1 May 27, 2009
Breast Cancer Journal Club Vol. 5, No. 2 Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer

Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab

Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC

Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer 		1 May 5, 2009
Case Studies in Breast Cancer Vol. 6, No. 1 ErbB TKIs in ErbB2-Positive IBC 1 May 5, 2009
Controversies in Adjuvant Endocrine Therapy for Breast Cancer Adjuvant Endocrine Therapy in 2007: What Have We Accomplished and What Uncertainties Remain?

Optimizing Endocrine Therapy for Patients With Newly Diagnosed Early-Stage Breast Cancer

Controversies in Adjuvant Endocrine Therapy: Extending Therapy Beyond 5 Years

Should All Patients Receiving Adjuvant Aromatase Inhibitors for Breast Cancer Receive Bisphosphonate Support? 		1 Apr 25, 2009
Clinical Challenges With Hereditary and Transfusion-Dependent Iron Overload
  • Hereditary Hemochromatosis and Iron Overload Disorders

  • Mechanisms of Action of Iron Chelating Agents

  • Current Perspectives in Measuring LIC

  • Managing Iron Overload in Transfusion-Dependent Patients

1 Apr 4, 2009
Clinical Breast Cancer Vol. 8, Suppl. 1 Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data

Management of Febrile Neutropenia and Cardiac Toxicity in the Adjuvant Treatment of Breast Cancer

Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors

New Strategies for the Treatment of Metastatic Bone Disease

 		1.5 Mar 3, 2009

Highlighted Publications


Practical Updates in Renal Cell Carcinoma

Expiration Date: Mar 3, 2009


Angiogenesis in Oncology Vol. 2, No. 6

Expiration Date: Jan 17, 2009